Interested in learning more about the MyRisk test and your ordering options? Fill out the form below to get started.
Request more information about how Myriad’s MyRisk Hereditary Cancer Test can benefit your patients.
By submitting your personal information, you agree to be contacted with newsletters, marketing or promotional materials, and other information that may be of interest to you. You may opt-out of receiving communications from us by following the unsubscribe link or the instructions provided in the communication we send. For further information on our privacy practices and commitment to protecting your privacy, please visit our Privacy Notice.
Contact Information
More than 1 in 4 patients you see today will meet criteria for hereditary cancer testing.1
Now featured in Obstetrics & Gynecology Learn more about how Myriad’s recently published study helps providers more than double the completion rate of the hereditary cancer risk assessment test.
Myriad’s comprehensive breast cancer risk assessment program can help your practice identify patients at high-risk for breast cancer, and provide resources for medical management.
8 out of 10 providers agreed that the program’s online screening tool helped them meet ACOG guidelines, recommending hereditary cancer risk assessment for all patients.2
Request more information about your hereditary genetic testing options and how MyRisk can benefit your patients.
A patient’s personal and family history could be the only sign that they are at an increased risk for breast cancer.
Accurate patient identification that fits any workflow:
Patient education:
The MyRisk hereditary cancer test evaluates genes associated with hereditary cancer, delivering unsurpassed technical accuracy with over 99.99% sensitivity and specificity.3
RiskScore is the first and only comprehensive breast cancer risk assessment that includes a polygenic score validated for all ancestries.
With over 99.99% sensitivity and specificity and the industry’s most definitive variant classification4, the MyRisk hereditary cancer test allows providers to accurately diagnose hereditary cancer syndromes associated with certain genetic mutations, such as BRCA1 and BRCA2, which are linked to an increased risk of breast and ovarian cancers.
For patients who test negative for breast cancer-associated genetic mutations, RiskScore provides eligible patients with a five-year and remaining lifetime risk of breast cancer, allowing providers to stratify breast cancer risk more comprehensively.
Patients and providers can make more confident and informed medical management decisions for managing risk.2
Myriad Genetics supports patients and healthcare providers throughout the genetic testing process, with pre-test educations with a board-certified genetic counselor, billing support, clear results reporting, and post-test consultations.
95% of private insurers have coverage for hereditary cancer testing.5
Myriad is committed to providing patients with access to accurate and affordable genetic results through extensive coverage with most insurance plans and financial assistance programs.
MyRisk Patient Story
Lisa’s mom’s battle with breast cancer inspired her to get genetic testing and make a life-saving choice. Her story is a testament to courage and resilience.